OR WAIT null SECS
Professor John McMurray explains why he is not as displeased as some colleagues are with the uptake of SGLT2 inhibitor prescribing rates for patients with heart failure or chronic kidney disease.
As part of their coverage of the American Heart Association (AHA) Scientific Sessions 2020, our sister publication Practical Cardiology has been busy interviewing leading experts in the field of cardiometabolic health. Among the most common talking points from this year’s annual meeting was further implementation of antihyperglycemic agents in real-world practice.
In the past 2 years, major outcomes trials have stolen the show at annual cardiology meetings, but now that focus has shifted to improving prescribing rates. However, there are still multiple presentations underlining new data and analyses from these major trials that continue to push our understanding of these drug classes forward.
For more on the topic of prescribing rates for SGLT2 inhibitors, check out this interview with John McMurray, MD, professor of cardiology at the University of Glasgow, as he offers his perspective in a recent AHA House Call.